Any respiratory illness in women · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in any respiratory illness in women compared with control (high certainty).
1 finding from 1 review
Any respiratory illness in infants · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in any respiratory illness in infants compared with control (high certainty).
1 finding from 1 review
Maternal hospitalisation for any infection · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in maternal hospitalisation for any infection compared with control (moderate certainty).
1 finding from 1 review
Neonatal hospitalisation due to sepsis within 28 days of birth · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in neonatal hospitalisation due to sepsis within 28 days of birth compared with control (moderate certainty).
1 finding from 1 review
Angiotensin receptor blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Intervention not reported
Angiotensin receptor blocker (high‐ versus medium‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin receptor blocker (medium‐ versus low‐dose) · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Angiotensin‐converting enzyme inhibitor · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus medium‐ dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Beta‐blocker (any dose) Mean duration of 4 weeks · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
2 findings from 1 review
Intervention not reported
High‐ versus medium‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
Medium‐ versus low‐dose · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High vs low dose Systolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review
Intervention not reported
High vs low dose Diastolic blood pressure · children (from 1 to 18 years of age) with hypertension from primary or secondary causes
1 finding from 1 review